Acurx Pharmaceuticals LLC (ACXP)

Acurx Pharmaceuticals LLC (ACXP) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $7.2M; returns 1 day -0.4%, 1 week +3.2%, 1 year -82.5%.

Acurx Pharmaceuticals, Inc. (ACXP) is a late-stage biopharmaceutical company focused on developing new antibiotics for difficult-to-treat bacterial infections. Their primary focus is on developing small molecule antibiotics that target the DNA polymerase IIIC enzyme. Acurx's lead drug candidate, ibezapolstat, is preparing for Phase 3 trials to treat *C. difficile* infections (CDI).

Groups ACXP belongs to

• Healthcare
• Biotechnology
• Pharmaceuticals
• Biopharmaceutical
• Clinical Stage Biotech
• Infectious Diseases
• Clinical Stage
• Drug Discovery
• Unmet Medical Needs

ACXP financial model: income statement, cash flow and balance sheet